🇺🇸 levo-folinic acid in United States
33 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 33
Most-reported reactions
- Nausea — 5 reports (15.15%)
- Paraesthesia — 5 reports (15.15%)
- Asthenia — 3 reports (9.09%)
- Back Pain — 3 reports (9.09%)
- Diarrhoea — 3 reports (9.09%)
- Hypertransaminasaemia — 3 reports (9.09%)
- Neutropenia — 3 reports (9.09%)
- Pyrexia — 3 reports (9.09%)
- Thrombocytopenia — 3 reports (9.09%)
- Cholangitis — 2 reports (6.06%)
Other Oncology approved in United States
Frequently asked questions
Is levo-folinic acid approved in United States?
levo-folinic acid does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for levo-folinic acid in United States?
National Cancer Institute, Naples is the originator. The local marketing authorisation holder may differ — check the official source linked above.